Annual Report 2023

Department of Hematopoietic Stem Cell Transplantation

Takahiro Fukuda, Sung-Won Kim, Yoshihiro Inamoto, Takashi Tanaka, Ayumu Ito, Wataru Takeda, Asako Usui

Introduction

 We specialize in patients who undergo allogeneic or autologous hematopoietic stem cell transplantation (HSCT). Our transplant units include 26 beds in ward 12B and 3 beds in ward 11A. All rooms are filtered by a central high-efficiency particulate air filtration system.

The Team and What We Do

 Seven staff physicians (Drs. Kim, Inamoto, Tanaka, Ito, Takeda, Usui and Fukuda) participate in the transplant program. Pediatric patients who undergo HSCT are managed in collaboration with Dr. Ogawa, the chief of the Department of Pediatric Oncology, and other pediatricians. In fiscal 2023, a total of 72 HSCTs were performed at the 12B and 12A transplant units. The number of each type of HCST performed in fiscal 2023 is shown in Table 1. The number of patients according to disease type is shown in Table 2.

 We discuss approximately 30 HSCT inpatients and those who consulted us for indication of HSCT every week at the collaborative conference on Monday with the Departments of Hematology and Pediatric Oncology. The transplant unit is staffed by 24 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing team has taken the leadership to facilitate improved care for graft-versus-host disease (GVHD), and to provide a long-term follow-up (LTFU) care and education to patients and their family members. In fiscal 2023, we saw a total of 344 patients at the LTFU clinic. We discuss all HSCT inpatients in detail among all transplant team members including physicians, nurses, pharmacists, the nutritional support team, the rehabilitation team, the mental support team, and the hematopoietic cell transplant coordinator (HCTC) every week on Friday.

Research Activities

 We started a new phase II multicenter trial to determine the safety and efficacy of PBSCT from an unrelated donor with post-transplant cyclophosphamide (PTCY) in patients with aggressive ATL in March 2021 (advanced medical care B). In August 2021, we started patient registration to a nationwide collaborative registry of patients with aggressive ATL of all age groups with AMED support. In addition, we started sample collection to a biorepository system in March 2022. By the end of March 2024, 534 patients and 245 samples were registered to the prospective study.

 We have published the following clinical studies: recurrent sick leave in survivors who returned to work after allogeneic HCT (Kurosawa, J Cancer Sruviv 2023), a randomized controlled trial to compare pneumococcal vaccines in allogeneic HCT recipients (Okinaka, Clin Microbiel Infect 2023), a registry study of pneumococcal diseases in allogeneic HCT recipients (Okinaka, J Infect Chemother 2023), scoring system for optimal cord blood unit selection (Watanabe, Cytotherapy 2024), impact of GVHD on lymphoma progression (Watanabe, Br J Haematol 2023), cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan (Watanabe, Blood Adv 2024), lenalidomide treatment for recurrent adult T-cell leukemia after allogeneic HCT (Tanaka, Hematol Oncol 2023), and nelarabine-induced myelopathy in patients undergoing allogeneic HCT (Fukuta, Int J Hematol 2023).

 In fiscal 2023, we have published 60 articles in peer-reviewed international journals

Education

 We have trained 6 residents to develop their clinical skills for management of HSCT patients in fiscal 2023.

Future Prospects

 Our goal is to develop optimal strategies for HSCT to achieve a cure for all patients with hematologic malignancies.

List of papers published in 2023

Journal

1. Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Masuko M, Murata M, Tashiro H, Kako S, Satake A, Hagihara M, Ota S, Saito T, Kagawa K, Matsuo Y, Itonaga H, Uoshima N, Yamaguchi H, Naito K, Takahashi M, Fukuda T. Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation. J Cancer Surviv. 2023 Jun;17(3):781-794. doi: 10.1007/s11764-022-01250-8. Epub 2022 Sep 1.PMID: 36048313

2. Okinaka K, Akeda Y, Inamoto Y, Fuji S, Ito A, Tanaka T, Kurosawa S, Kim SW, Tanosaki R, Yamashita T, Ohwada C, Kurata K, Mori T, Onozawa M, Takano K, Yokoyama H, Koh K, Nagafuji K, Nakayama K, Sakura T, Takahashi T, Oishi K, Fukuda T. Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial. Clin Microbiol Infect. 2023 Apr;29(4):482-489. doi: 10.1016/j.cmi.2022.12.007. Epub 2022 Dec 8.PMID: 36503114

3. Okinaka K, Inoue Y, Uchida N, Toya T, Ogawa H, Ozawa Y, Eto T, Mori T, Sugita J, Kondo T, Kato K, Suzuki R, Fukuda T. Clinical characteristics and risk factors of pneumococcal diseases in recipients of allogeneic hematopoietic stem cell transplants in the late phase: A retrospective registry study. J Infect Chemother. 2023 Jul;29(7):726-730. doi: 10.1016/j.jiac.2023.04.015. Epub 2023 Apr 22.PMID: 37088144

4. Watanabe M, Konuma T, Imahashi N, Terakura S, Seo S, Morishima S, Uchida N, Doki N, Tanaka M, Nishida T, Kawakita T, Eto T, Takahashi S, Sawa M, Uehara Y, Kim SW, Ishimaru F, Ichinohe T, Fukuda T, Atsuta Y, Kanda J. Scoring system for optimal cord blood unit selection for single cord blood transplantation. Cytotherapy. 2024 Mar;26(3):286-298. doi: 10.1016/j.jcyt.2023.12.001. Epub 2023 Dec 27.PMID: 38149949

5. Watanabe M, Kanda J, Fukuda T, Uchida N, Ikegame K, Kataoka K, Kobayashi H, Ara T, Ishikawa J, Matsuoka KI, Sugio Y, Nakazawa H, Ikeda T, Atsuta Y, Kondo E, Suzuki R; Japanese Society for Transplantation and Cellular Therapy, Adult Lymphoma Working Group. Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy. Br J Haematol. 2023 Nov;203(3):446-459. doi: 10.1111/bjh.19041. Epub 2023 Aug 23.PMID: 37614023

6. Watanabe M, Kanda J, Volt F, Ruggeri A, Suzuki R, Rafii H, Kimura F, Cappelli B, Kondo E, Scigliuolo GM, Takahashi S, Kenzey C, Rivera-Franco MM, Okamoto S, Rocha V, Chevallier P, Sanz J, Fürst S, Cornelissen J, Milpied N, Uchida N, Sugio Y, Kimura T, Ichinohe T, Fukuda T, Mohty M, Peffault de Latour R, Atsuta Y, Gluckman E. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan. Blood Adv. 2024 Feb 13;8(3):640-652. doi: 10.1182/bloodadvances.2023010598.PMID: 38100431 Free PMC article.

7. Tanaka T, Inamoto Y, Ito A, Watanabe M, Takeda W, Aoki J, Kim SW, Fukuda T. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. Hematol Oncol. 2023 Aug;41(3):389-395. doi: 10.1002/hon.3115. Epub 2022 Dec 19.PMID: 36513602

8. Fukuta T, Tanaka T, Hashimoto T, Isahaya K, Kubo Y, Yamano Y, Satomi K, Hiraoka N, Shirakawa N, Arakawa A, Ogawa C, Nishimura N, Aoki J, Ito A, Inamoto Y, Kim SW, Fukuda T. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases. Int J Hematol. 2023 Jun;117(6):933-940. doi: 10.1007/s12185-023-03539-5. Epub 2023 Jan 27.PMID: 36705847

9. Inamoto Y. Calculate Your Risk of Heart Attack After Hematopoietic Cell Transplantation. JACC CardioOncol. 2023 Aug 15;5(4):518-519. doi: 10.1016/j.jaccao.2023.04.007. eCollection 2023 Aug.PMID: 37614583 Free PMC article.

10. Tsubokura M, Kojima M, Nakabayashi S, Takahashi N, Takeuchi S, Aruga Y, Ikeda C, Maezawa N, Okazaki K, Uchida S, Watanabe M, Aoki J, Ito A, Tanaka T, Inamoto Y, Kim SW, Matsushita H, Fukuda T. EDTA-induced pseudothrombocytopenia in hematopoietic stem cell donor. Clin Case Rep. 2023 Apr 5;11(4):e7023. doi: 10.1002/ccr3.7023. eCollection 2023 Apr.PMID: 37035607 Free PMC article.

11. Tao K, Inamoto Y, Furukawa H, Hosoba R, Takeda W, Maeshima A, Aoki J, Ito A, Tanaka T, Kim SW, Makita S, Fukuhara S, Kogure Y, Kataoka K, Izutsu K, Fukuda T. Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation. Int J Hematol. 2023 Aug;118(2):292-298. doi: 10.1007/s12185-023-03561-7. Epub 2023 Feb 20.PMID: 36807258

12. Sugiyama M, Arakawa A, Kogure Y, Shirakawa N, Watanabe M, Ito Y, Tanimura K, Tao K, Nakajima M, Watanabe Y, Miyagi-Maeshima A, Fukuhara S, Kataoka K, Izutsu K, Fukuda T, Ogawa C. Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission. Pediatr Blood Cancer. 2024 Jan;71(1):e30721. doi: 10.1002/pbc.30721. Epub 2023 Oct 13.PMID: 37833848 No abstract available.

13. Mizuno S, Takami A, Kawamura K, Harada K, Masayoshi M, Yano S, Ito A, Ozawa Y, Ouchi F, Ashida T, Nawa Y, Ichinohe T, Fukuda T, Atsuta Y, Yanada M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion. EJHaem. 2024 Mar 30;5(2):369-378. doi: 10.1002/jha2.877. eCollection 2024 Apr. PMID: 38633128 Free PMC article.

14. Yanagisawa R, Shindo M, Shinohara A, Kuwatsuka Y, Nakase K, Kimura F, Shingai N, Nishida T, Fukuda T, Sakurai M, Kurokawa M, Koike T, Ota S, Takada S, Onizuka M, Uchida N, Tanaka M, Noguchi M, Maruyama Y, Hagihara M, Ichinohe T, Atsuta Y, Kanda J, Nakasone H, Toubai T.Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations. Transplant Proc. 2024 Mar;56(2):416-421. doi: 10.1016/j.transproceed.2024.01.049. Epub 2024 Feb 9.PMID: 38336483

15. Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, Ara T, Eto T, Mori Y, Matsuoka KI, Kanda Y, Onizuka M, Atsuta Y, Ichinohe T, Morishima S, Kanda J; JSTCT HLA Working Group. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis. Int J Hematol. 2024 Feb;119(2):173-182. doi: 10.1007/s12185-023-03693-w. Epub 2024 Jan 17.PMID: 38233701

16. Shimomura Y, Kitamura T, Murata M, Matsuo K, Ito Y, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, Sato A, Onizuka M, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Fukuda T, Kanda J, Terakura S. Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar;30(3):326.e1-326.e14. doi: 10.1016/j.jtct.2024.01.056. Epub 2024 Jan 11.PMID: 38218451

17. Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, Katayama Y, Hiramoto N, Nakano N, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Kanda J. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Am J Hematol. 2024 Feb;99(2):263-273. doi: 10.1002/ajh.27174. Epub 2024 Jan 2.PMID: 38164974

18. Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Uehara Y, Maruyama Y, Ishiwata K, Kawakita T, Sawa M, Eto T, Ishimaru F, Kato K, Fukuda T, Atsuta Y, Kanda J, Yakushijin K, Nakasone H. Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score. Blood Adv. 2024 Mar 26;8(6):1359-1368. doi: 10.1182/bloodadvances.2023011837.PMID: 38163321 Free PMC article.

19. Yanada M, Yamasaki S, Kondo T, Kawata T, Harada K, Uchida N, Doki N, Yoshihara S, Katayama Y, Eto T, Tanaka M, Takada S, Kawakita T, Nishida T, Ota S, Serizawa K, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Konuma T. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. Leukemia. 2024 Mar;38(3):513-520. doi: 10.1038/s41375-023-02119-0. Epub 2023 Dec 21.PMID: 38129514

20. Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara SI, Katayama Y, Sawa M, Serizawa K, Matsuoka KI, Uchida N, Ikeda T, Ohigashi H, Fukushima K, Hino M, Kanda Y, Fukuda T, Atsuta Y, Kanda J. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Cytotherapy. 2024 Feb;26(2):178-184. doi: 10.1016/j.jcyt.2023.11.012. Epub 2023 Dec 16.PMID: 38108686

21. Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, Matsuoka KI, Kanda Y, Maruyama Y, Sawa M, Eto T, Hiramoto N, Fukuda T, Atsuta Y, Nakamae H. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transplant Cell Ther. 2024 Mar;30(3):316.e1-316.e12. doi: 10.1016/j.jtct.2023.10.021. Epub 2023 Oct 30.PMID: 38108263

22. Nakano N, Nakasone H, Fuji S, Shinohara A, Suzuki R, Utsunomiya A, Eto T, Morishima S, Ikegame K, Kakinoki Y, Matsuoka KI, Mori Y, Suehiro Y, Uchida N, Ito A, Doki N, Ozawa Y, Kanda J, Kanda Y, Fukuda T, Atsuta Y, Ogata M. Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey. .Lancet Reg Health West Pac. 2023 Sep 25;40:100902. doi: 10.1016/j.lanwpc.2023.100902. eCollection 2023 Nov.PMID: 38106528

23. Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, Ikegame K, Matsuoka KI, Katayama Y, Kanda Y, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Shinohara A, Nakasone H. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):325-333. doi: 10.1038/s41409-023-02172-4. Epub 2023 Dec 16.PMID: 38104219

24. Kato K, Sugio T, Ikeda T, Yoshitsugu K, Miyazaki K, Suzumiya J, Yamamoto G, Kim SW, Ikegame K, Uehara Y, Mori Y, Ishikawa J, Hiramoto N, Eto T, Nakazawa H, Kobayashi H, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Suzuki R. Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2024 Mar;59(3):306-314. doi: 10.1038/s41409-023-02156-4. Epub 2023 Dec 15.PMID: 38102209

25. Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, Ishiwata K, Sawa M, Tanaka T, Ohigashi H, Fujiwara SI, Matsuoka KI, Ota S, Nishida T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Yanada M; Adult Acute Myeloid Leukemia and Donor/source Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status. Transplant Cell Ther. 2024 Feb;30(2):215.e1-215.e18. doi: 10.1016/j.jtct.2023.12.002. Epub 2023 Dec 9.PMID: 38081415

26. Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30.PMID: 38037468

27. Takenaka K, Fuji S, Matsukawa T, Uchida N, Kobayashi T, Tanaka M, Ara T, Ikegame K, Ozawa Y, Kanda Y, Sawa M, Maruyama Y, Fukuda T, Nakamae H, Kimura T, Ogata M, Seo S, Atsuta Y, Matsuo K, Nakasone H. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection. Ann Hematol. 2024 Jan;103(1):285-296. doi: 10.1007/s00277-023-05474-1. Epub 2023 Nov 10.PMID: 37947825

28. Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28.PMID: 37898725

29. Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, Sawa M, Ueda Y, Nakamae H, Nawa Y, Tanaka M, Arai Y, Ota S, Kataoka K, Nishida T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024 Feb;204(2):612-622. doi: 10.1111/bjh.19139. Epub 2023 Oct 19.PMID: 37857379

30. Koresawa-Shimizu R, Suzuki R, Uehara Y, Hiramoto N, Sawa M, Fukuda T, Kataoka K, Kanda Y, Oyake T, Kubota Y, Uchida N, Yano S, Kobayashi H, Tanaka J, Atsuta Y, Kondo E. Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry. Bone Marrow Transplant. 2024 Jan;59(1):125-127. doi: 10.1038/s41409-023-02118-w. Epub 2023 Oct 7.PMID: 37805626 No abstract available.

31. Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, Fujiwara H, Nishida T, Hayashi M, Tanaka M, Kawakita T, Ikegame K, Katayama Y, Ara T, Ichinohe T, Kiyoi H, Matsuo K, Atsuta Y. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades. Transplant Cell Ther. 2023 Dec;29(12):768.e1-768.e10. doi: 10.1016/j.jtct.2023.09.010. Epub 2023 Sep 21.PMID: 37739224

32. Fuji S, Hakoda A, Kanda J, Fukuda T, Doki N, Katayama Y, Uchida N, Ozawa Y, Kanda Y, Tanaka M, Kataoka K, Ara T, Sawa M, Onizuka M, Onishi Y, Kimura T, Ichinohe T, Atsuta Y, Shintani A, Morishima S. Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023 Nov;58(11):1257-1259. doi: 10.1038/s41409-023-02076-3. Epub 2023 Aug 7.PMID: 37550450 No abstract available.

33. Hirabayashi S, Kondo T, Nishiwaki S, Mizuta S, Doki N, Fukuda T, Uchida N, Ozawa Y, Kanda Y, Imanaka R, Takahashi S, Ishikawa J, Yano S, Nakamae H, Eto T, Kimura T, Tanaka J, Ichinohe T, Atsuta Y, Kako S. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph(+) ALL: A retrospective nationwide study. Am J Hematol. 2023 Oct;98(10):1606-1618. doi: 10.1002/ajh.27041. Epub 2023 Jul 26.PMID: 37493218 Free article.

34. Araie H, Arai Y, Kida M, Aoki J, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Sawa M, Katayama Y, Matsuo Y, Onizuka M, Kanda Y, Kawakita T, Kanda J, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol. 2023 Oct;102(10):2879-2893. doi: 10.1007/s00277-023-05356-6. Epub 2023 Jul 21.PMID: 37477669 Free PMC article.

35. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. Hemasphere. 2023 Jun 8;7(6):e899. doi: 10.1097/HS9.0000000000000899. eCollection 2023 Jun.PMID: 37475881 Free PMC article. No abstract available.

36. Yanada M, Shimomura Y, Mizuno S, Matsuda K, Kondo T, Doki N, Tanaka M, Fukuda T, Ara T, Uchida N, Onizuka M, Sawa M, Ozawa Y, Hiramoto N, Ota S, Kanda J, Kanda Y, Ichinohe T, Okamoto S, Atsuta Y, Konuma T. External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia. Bone Marrow Transplant. 2023 Oct;58(10):1096-1103. doi: 10.1038/s41409-023-02037-w. Epub 2023 Jul 13.PMID: 37443251

37. Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, Kako S, Tsukada N, Kanda Y, Kurahashi S, Doki N, Nishikawa A, Kim SW, Hangaishi A, Kanda J, Fukuda T, Atsuta Y, Kondo E, Kawamura K, Nakasone H. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy. 2023 Nov;25(11):1212-1219. doi: 10.1016/j.jcyt.2023.05.015. Epub 2023 Jun 24.PMID: 37354150

38. Tamaki M, Akahoshi Y, Okada Y, Uchida N, Tanaka M, Doki N, Sawa M, Maruyama Y, Ueda Y, Miyakoshi S, Katayama Y, Kawakita T, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Kanda J, Nakasone H. Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients. Cytotherapy. 2023 Nov;25(11):1220-1228. doi: 10.1016/j.jcyt.2023.06.002. Epub 2023 Jun 20.PMID: 37341665

39. Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, Katayama Y, Ozawa Y, Matsuoka KI, Kawakita T, Mori Y, Ara T, Nakamae H, Kimura T, Kanda Y, Atsuta Y, Ogata M; Transplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy. Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group. Ann Hematol. 2023 Sep;102(9):2507-2516. doi: 10.1007/s00277-023-05320-4. Epub 2023 Jun 20.PMID: 37338625

40. Fujii N, Onizuka M, Fukuda T, Ikegame K, Kawakita T, Nakamae H, Kobayashi T, Kataoka K, Tanaka M, Kondo T, Kato K, Sato A, Ichinohe T, Atsuta Y, Ogata M, Suzuki R, Nakasone H; JSTCT Transplant Complications Working Group. Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2023 Aug;118(2):242-251. doi: 10.1007/s12185-023-03624-9. Epub 2023 Jun 9.PMID: 37296337

41. Jo T, Arai Y, Oshima S, Kondo T, Harada K, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Kuriyama T, Ikegame K, Katayama Y, Ota S, Ara T, Kawakita T, Onizuka M, Ichinohe T, Atsuta Y, Yanada M; Japanese Society for Transplantation and Cellular Therapy (JSTCT). Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach. Br J Haematol. 2023 Jul;202(2):356-368. doi: 10.1111/bjh.18855. Epub 2023 May 21.PMID: 37211753 Free article.

42. Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, Ara T, Kuriyama T, Katayama Y, Kawakita T, Kanda Y, Onizuka M, Ichinohe T, Atsuta Y, Terakura S. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023 May 16;3(1):67. doi: 10.1038/s43856-023-00299-5.PMID: 37193882 Free PMC article.

43. Inoue Y, Morishima S, Kato K, Ito A, Nakano N, Kuriyama T, Kawakita T, Mori Y, Suehiro Y, Itonaga H, Miyazaki Y, Imada K, Tomori S, Kanda J, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2023 Sep;58(9):980-990. doi: 10.1038/s41409-023-02002-7. Epub 2023 May 12.PMID: 37173417

44. Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, Miyakoshi S, Ozawa Y, Fukuda T, Matsuoka KI, Tanaka J, Kimura T, Ichinohe T, Atsuta Y. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome? Bone Marrow Transplant. 2023 Aug;58(8):893-906. doi: 10.1038/s41409-023-01997-3. Epub 2023 May 8.PMID: 37156881 Free PMC article.

45. Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim SW, Ozawa Y, Fujiwara SI, Kako S, Matsuoka KI, Sawa M, Katayama Y, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Yakushijin K, Nakasone H. Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023 May 3;13(1):7166. doi: 10.1038/s41598-023-34442-y.PMID: 37138004 Free PMC article.

46. Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, Mori Y, Uchida N, Morishima S, Onizuka M, Ishitsuka K, Fukuda T, Atsuta Y, Yoshimitsu M. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023 Jun;58(6):729-731. doi: 10.1038/s41409-023-01969-7. Epub 2023 Mar 25.PMID: 36966214 No abstract available.

47. Itonaga H, Miyazaki Y, Aoki K, Shingai N, Ozawa Y, Fukuda T, Kataoka K, Kawakita T, Ueda Y, Ara T, Tanaka M, Katayama Y, Sawa M, Eto T, Kanda J, Atsuta Y, Ishiyama K. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. Ann Hematol. 2023 May;102(5):1215-1227. doi: 10.1007/s00277-023-05167-9. Epub 2023 Mar 15.PMID: 36918415

48. Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, Eto T, Takada S, Kako S, Uchida N, Kawakita T, Yoshiko H, Ichinohe T, Atsuta Y, Terakura S; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation. Int J Hematol. 2023 Jun;117(6):889-899. doi: 10.1007/s12185-023-03563-5. Epub 2023 Feb 22.PMID: 36814041

49. Shibata S, Arai Y, Kondo T, Mizuno S, Harada K, Miyakoshi S, Uchida N, Maruyama Y, Eto T, Katsuoka Y, Matsue K, Nishiwaki K, Takada S, Doki N, Itoh M, Nagafuji K, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Yanada M. Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplant Cell Ther. 2023 May;29(5):332.e1-332.e11. doi: 10.1016/j.jtct.2023.02.004. Epub 2023 Feb 14.PMID: 36796517 Free article.

50. Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Ishitsuka K, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M, Kato K. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. Bone Marrow Transplant. 2023 Apr;58(4):462-464. doi: 10.1038/s41409-023-01919-3. Epub 2023 Jan 21.PMID: 36681773 No abstract available.

51. Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. Blood Adv. 2023 Jun 27;7(12):2699-2708. doi: 10.1182/bloodadvances.2022009376.PMID: 36661335 Free PMC article.

52. Kaida K, Ikegame K, Inoue T, Maruyama S, Ishii S, Uchida N, Doki N, Eto T, Fukuda T, Katayama Y, Takada S, Kawakita T, Ichinohe T, Atsuta Y, Daimon T, Ogawa H. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types. Transplant Cell Ther. 2023 Apr;29(4):273.e1-273.e9. doi: 10.1016/j.jtct.2023.01.005. Epub 2023 Jan 12.PMID: 36641032 Free article.

53. Konuma T, Itonaga H, Ishiyama K, Hamamura A, Uchida N, Ozawa Y, Katayama Y, Sakurai M, Ueda Y, Matsuoka KI, Kawakita T, Eto T, Ara T, Kanda J, Onizuka M, Fukuda T, Atsuta Y. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real-world registry study in Japan. Am J Hematol. 2023 Apr;98(4):E68-E71. doi: 10.1002/ajh.26839. Epub 2023 Jan 24.PMID: 36633538 Free article. No abstract available.

54. Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023 Apr;114(4):1297-1308. doi: 10.1111/cas.15720. Epub 2023 Jan 27.PMID: 36610002 Free PMC article.

55. Shimomura Y, Kitamura T, Nishikubo M, Sobue T, Uchida N, Doki N, Tanaka M, Ito A, Ishikawa J, Ara T, Ota S, Onizuka M, Sawa M, Ozawa Y, Maruyama Y, Ikegame K, Kanda Y, Ichinohe T, Fukuda T, Okamoto S, Teshima T, Atsuta Y. Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan. Int J Hematol. 2023 Apr;117(4):590-597. doi: 10.1007/s12185-022-03508-4. Epub 2022 Dec 14.PMID: 36515796 Free PMC article.

56. Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, Fukuda T, Tanaka M, Sawa M, Katayama Y, Matsuoka KI, Ozawa Y, Onizuka M, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv. 2023 Sep 12;7(17):4738-4747. doi: 10.1182/bloodadvances.2022008706.PMID: 36508283 Free PMC article.

57. Yanagisawa R, Tamaki M, Tanoshima R, Misaki Y, Uchida N, Koi S, Tanaka T, Ozawa Y, Matsuo Y, Tanaka M, Ikegame K, Katayama Y, Matsuoka KI, Ara T, Kanda Y, Matsumoto K, Fukuda T, Atsuta Y, Kato M, Nakasone H. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group. Hematol Oncol. 2023 Aug;41(3):535-545. doi: 10.1002/hon.3101. Epub 2022 Nov 25.PMID: 36385399

58. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, Bhatt N, Bhatt VR, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Hashmi S, Hematti P, Hossain NM, Inamoto Y, Lekakis LJ, Sharma A, Solomon S, Lee SJ, Couriel DR. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2024 Jan;30(1):97.e1-97.e14. doi: 10.1016/j.jtct.2023.10.010. Epub 2023 Oct 14.PMID: 37844687

59. Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023 Oct;29(10):594-597. doi: 10.1016/j.jtct.2023.07.002. Epub 2023 Jul 6.PMID: 37422194 Free article.

60. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 1;108(7):1900-1908. doi: 10.3324/haematol.2022.281958.PMID: 36779595